Abstract Because of low incidence, mixed study populations and paucity of clinical and histological data, the management of adult brainstem gliomas (BSGs) remains non-standardized. We here describe characteristics, treatment and outcome of patients with exclusively histologically confirmed adult BSGs. A retrospective chart review of adults (age [18 years) was conducted. BSG was defined as a glial tumor located in the midbrain, pons or medulla. Characteristics, management and outcome were analyzed. Twenty one patients (17 males; median age 41 years) were diagnosed between 2004 and 2012 by biopsy (n = 15), partial (n = 4) or complete resection (n = 2). Diagnoses were glioblastoma (WHO grade IV, n = 6), anaplastic astrocytoma (WHO grade III, n = 7), diffuse astrocytoma (WHO grade II, n = 6) and pilocytic astrocytoma (WHO grade I, n = 2). Diffuse gliomas were mainly located in the pons and frequently showed MRI contrast enhancement. Endophytic growth was common (16 vs. 5). Postoperative therapy in low-grade (WHO grade I/II) and high-grade gliomas (WHO grade III/IV) consisted of radiotherapy alone (three in each group), radiochemotherapy (2 vs. 6), chemotherapy alone (0 vs. 2) or no postoperative therapy (3 vs. 1). Median PFS (24.1 vs. 5.8 months; log-rank, p = 0.009) and mOS (30.5 vs. 11.5 months; log-rank, p = 0.028) was significantly better in WHO grade II than in WHO grade III/IV tumors. Second-line therapy considerably varied. Histologically verification of adult BSGs is feasible and has an impact on postoperative treatment. Low-grade gliomas can simple be followed or treated with radiotherapy alone. Radiochemotherapy with temozolomide can safely be prescribed for high-grade gliomas without additional CNS toxicities.
Introduction
Brainstem gliomas (BSGs) are devastating malignancies of the central nervous system (CNS) and comprise 1-2 % of adult primary brain tumors [1, 2] . The median overall survival (mOS) is reported to be 5 years in diffuse intrinsic low-grade BSGs (LG-BSG) [1] . High-grade BSGs (HGBSGs) are associated with greater morbidity and mortality with a mOS ranging from 11 to 17 months [3] [4] [5] . In three out of four patients the tumor is localized in the pontine region, both in adults and in children [2, 5] . The midbrain and the cervico-medullary region are less commonly affected. Based on magnetic resonance imaging (MRI) four phenotypes can be defined: (1) non-enhancing, diffuse intrinsic glioma; (2) localized enhancing lesions; (3) focal tectal gliomas; and (4) other patterns [3] . Stereotactic brainstem biopsy should be the diagnostic standard of care in adults with enhancing lesions as it has the greatest impact on therapeutic decisions [1, 6] . With stereotactic biopsy a definitive diagnosis can be obtained in over 95 % of the patients [7] . Despite reluctance of clinicians for biopsy and exclusive radiological diagnosis for recent years [5] , the complication rate of stereotactic biopsy in experienced hands is low. Persistent disability and mortality has been reported at 1.7 and 0.9 %, respectively [7] . On multivariate analysis short duration of symptoms, necrosis on MRI and higher histological grade were independent negative prognostic factors [3] . Kesari et al. [4] identified non-caucasian ethnicity, higher age, higher tumor grade and pontine tumor location as poor prognostic factors for survival. A short time between symptom onset and diagnosis was also associated with a worse outcome of diffuse BSGs [5, 8] .
Depending on severity of symptoms and tumor grade, radiotherapy has historically been the treatment of choice [2, 8] . However, irradiation doses vary among the reported series [3, 4, [8] [9] [10] . A few recent reports have administered concomitant radiochemotherapy with temozolomide [8, 9] , however prospective protocols in a pediatric population were disappointing [11] [12] [13] [14] . No agreement in the management of recurrent or progressive BSGs exists.
Most recent reports were not only retrospective studies, but often analyzed a mixed patient population of both adults and children [2, 10] and contained a substantial proportion of patients without histological verification of the presumed diagnosis [3, 4, 8] . Only one recent case series with histologically verified tumors in patients older than 60 years was published [9] . Hence, due to the paucity of data, clinical decisions for individual patients remain challenging, and an established treatment other than radiotherapy does not exist. In this study we describe the diagnosis, clinical management and outcome in a cohort of adult patients with histologically verified LG-and HG-BSG.
Patients and methods
We performed a retrospective review of records of adult patients ([18 years) treated for BSG at four neuro-oncology centers in Switzerland between 2004 and 2012. This study was approved by the institutional ethic committee.
BSGs were defined as tumors with the main mass in the midbrain, pons or medulla [3] . Gliomas with extension to the cerebellum, the thalamus and the spinal cord were also included. Histological confirmation of the diagnosis of BSG was required to include patients in this study. BSGs of any grade were accepted. Ependymomas as a distinct clinical and molecular entity were excluded.
Clinical data comprised age at diagnosis, gender, time from first imaging to histological diagnosis, presenting signs and symptoms, location, treatment complications and neurological deterioration after surgery, written reports of cerebral MRI images (T1-and T2-weight images in two planes before and after gadolinium) and written pathological reports. Results of molecular analyses were also collected. Data of first-line and follow-up therapy including degree of surgery (biopsy, resection), dose and timing of radiotherapy and chemotherapy were included. Outcome was calculated for median progression free survival (mPFS) and mOS based on the Kaplan-Meier estimates [15] . Survival curves were compared with the log-rank test (Mantel-Cox). PFS and OS of first-line therapy were defined from initial histological diagnosis to clinical and/or radiological progression or death.
Results

Characteristics
Twenty-one adult patients were identified (17 males) from local data basis of the participating centers. Median age at surgery was 41 years (range 20-81). Patients with HGBSGs were older than those with LG-BSGs (median 48 vs. 34 years, t test; p = 0.56). The median time from initial imaging to surgery was approximately 2 months in both groups. The main clinical symptoms at presentation were ataxia, oculomotor symptoms, dizziness and a sensory and/ or motor hemisyndrome (Table 1) . Most BSGs were located in the pons (n = 8). Additionally, seven BSGs extended from the pons to the midbrain or medulla (Table 1) . Typical tectal gliomas were not present. More than half of the gliomas showed contrast enhancement on the initial MRI (13 vs. 8; Table 1 ). Exophytic tumor growth was rare (n = 5; Table 1 ). Representative MRIs are shown in Fig. 1 .
Histology and molecular biology
Histological diagnosis was mainly achieved by biopsy (n = 15; Table 1 ). A minority of patients underwent a partial resection (n = 4). Two pilocytic astrocytomas (WHO grade I) were macroscopically resected. In all 13 gadolinium-enhancing LG-and HG-BSGs the tumor samples were derived from areas of contrast enhancement. Histological diagnosis revealed glioblastoma (WHO grade IV, n = 6), anaplastic astrocytoma (WHO grade III, n = 7) and diffuse astrocytoma (WHO grade II, n = 6) ( Table 2 ). There were no oligodendrogliomas or mixed oligoastrocytic gliomas.
Molecular analysis was available in only seven cases (Table 2 ) mainly due to the limited tumor material and non-standardized institutional guidelines for diagnostic work-up. IDH 1/2 wild-type status was determined in one LG-and three HG-BSGs. A germline p53 mutation was found in a GBM patient suffering from a Li-Fraumeni syndrome. In one LG-BSG the p53 gene was determined as wild type. The MGMT promoter region was unmethylated in two HG-BSGs. Loss of heterozygosity of chromosome 1p and 19q was absent in one patient with an anaplastic astrocytoma.
Therapy and outcome
At the time of analysis (August 2013) nine patients are still alive and 12 have died from progressive disease. The median follow-up of patients being alive is 23.9 months. Neurological deterioration was observed in three patients after biopsy (patients 10, 12) or gross total resection (patient 2) ( Table 1 ). In patient two permanent postoperative oculomotor symptoms persisted. In patients 10 and 12 pre-existing hemi-hypoesthesia and dysphagia initially worsened but partially recovered within months. Treatment and outcome after diagnosis are summarized in Table 3 . Radiotherapy was given to 15 patients, temozolomide chemotherapy was administered concomitantly in nine patients. In two patients with high-grade tumors chemotherapy alone was prescribed postoperatively (temozolomide). Irradiation was rejected because of previous prophylactic CNS irradiation for a hematologic neoplasia (patient 10) or to avoid clinical deterioration due to radiation-induced edema (patient 13). Focal fractionated external beam irradiation was delivered to a median dose of 54 Gy in conventional fractionation (range 50.4-55.8 Gy). HGG were treated to a median dose of 57.6 Gy, with doses varying widely from two patients being treated with a hypofractionated regimen with 39.75 Gy in 15 fractions, to patients treated in conventional fractionation (1.8-2 Gy) from 45 to 60 Gy. Stereotactic radiosurgery was neither prescribed for initial nor for recurrent disease. No postoperative therapy was recommended for three patients with
LG-BSGs, while in one of them, rapid tumor progression did not allow further antitumor therapy. Durable disease stabilization from 7.3 to 95.8 months was observed in five patients with LG-BSGs. Three patients with HG-BSGs and one patient with a LG-BSG died of progressive disease after initial treatment. Ten patients with HG-BSGs and two patients with LG-BSGs progressed. We excluded two patients with a pilocytic astrocytoma as a different disease entity in the outcome analysis (Fig. 2) . Median PFS of LG-BSG was significantly better with 24.1 months compared to 5.8 months in a b Fig. 1 Transversal MRI scans of a medullary low-grade brainstem glioma (a T1-weighted, T1-weighted ? gadolinium; T2-weighted) and a ponto-medullary glioblastoma of the brainstem (b T1-weighted, T1-weighted ? gadolinium; T2-weighted). The glioma is indicated with a white arrow HG-BSGs, respectively (log-rank, p = 0.009). Subsequent salvage therapy consisted of anti-VEGF treatment with bevacizumab (n = 4), and chemotherapy with temozolomide (n = 4) or lomustine (n = 2). One patient each underwent salvage radiotherapy or radiochemotherapy at progression after failure of initial chemotherapy. Third-line therapy in HG-BSGs consisted of bevacizumab in three patients. None of the patients underwent a second surgery or any kind of re-irradiation for progressive disease.
Median OS in patients suffering from LG-BSGs (n = 6) and HG-BSGs (n = 13) was statistically different with 30.5 and 11.5 months, respectively (log-rank, p = 0.028) ( Table 3 ; Fig. 2b ). Log-rank test of mPFS and mOS of contrast enhancing versus non-contrast enhancing BSGs were statistically not significant.
Discussion
The current study represents the largest contemporary clinical investigations of histologically verified adult BSGs. Most recent studies on BSG were retrospective case series with small and heterogeneous cohorts. All but one series [9] mixed adults and children [2, 8, [16] [17] [18] [19] , various proportions of histologically non-verified brainstem lesions ranging from 10 to 72 % [2-4, 8, 10, 16-19] or a combination of both [2, 8, [16] [17] [18] [19] . The only prospective study investigated fractionated stereotactic radiotherapy in both pediatric and adult patients, and included many patients without histological diagnosis [18] . The impact of nonmalignant or even non-glial lesions (i.e. metastasis, inflammation) [6, 20] , distinct molecular pathology of histone H3 alterations in pediatric BSGs [21] and different prognosis in children and adults remains elusive [2, 4] . Histological verification of suspected brainstem tumors is key for appropriate subsequent therapy as the concordance of MRI imaging and histological diagnosis is low. The presumed glioma diagnosis in a cohort of 30 patients could histologically be confirmed in only 63 %, the others being lymphomas, metastasis or inflammatory lesions [6] . This finding underscores the importance of exact histological diagnosis before making clinical treatment decisions [20, 22] . Most series do not distinguish between low-and highgrade gliomas, although the prognosis and outcome is greatly influenced by tumor grade. In one study survival of diffuse intrinsic LG-BSG was 7.3 years compared with only 12 months in patients with HG-BSGs [3] . In our cohort only histologically confirmed glial tumors of adults were included. Median age of LG-BSG was lower (34 vs. 48 years) and outcome measured in terms of mPFS and mOS was as expected better than in high grade tumors (Fig. 1a, b) . Interestingly, contrast enhancement on MRI was also commonly detected in LG-BSGs. This has already been reported in a correlation study of MRI findings and histologically verified brainstem lesions and is also observed in pediatric LG-BSG [23] . Although contrast enhancement in low-grade gliomas of supratentorial localization are frequently associated with an oligodendroglial histology, oligodendrogliomas are rarely the cause for BSGs [24] . Our cohort did also not contain any brainstem oligodendroglioma [2-4, 8, 9] . Histological grading of BSGs might be limited due to small and non-representative specimens of the tumor for histological diagnosis. This especially accounts for biopsies. However, in our cohort all patients with contrast enhancement on the preoperative MRI tumor tissue were derived from a gadolinium enhancing area which contributes to the quality of histological diagnosis.
By its location, BSGs poses particular challenges to treatment with radiotherapy. Large parts of the planning process for non-BSGs are devoted to sparing the brainstem of higher doses. This is obviously not possible in BSG. In the 1990s, dose constraints were often based on the Emami review, which at the time of publication in 1991, specified a 5-year, 5 %-rate of ''necrosis/infarct'' would result from 50, 53, and 60 Gy delivered to the whole, two-thirds, and one-third of the brainstem, respectively [25] . Several trials have subsequently defined the dose-maximum constraints to the brainstem to be in the range of 50-55 Gy. Newer analyses estimate that the entire brainstem may be treated to 54 Gy using conventional fractionation with limited risk of severe or permanent neurological deficits [26] . Smaller volumes of the brainstem (1-10 cc) may be irradiated to maximum doses of 59 Gy for dose fractions B2 Gy. The risk appears to increase markedly at doses [64 Gy. However, there is insufficient information to determine whether there is a further volume effect [27] . The large variations of applied radiotherapy doses in our study reflect the lack of a well-established standard of care. In our series we did not observe any radiotherapy associated brainstem injury, and no increase in toxicity was seen in patients who received concomitant and adjuvant temozolomide. The current literature so far reported only common hematological toxicities in adults receiving concomitant and adjuvant temozolomide for BSG [8, 9] . This is a clinical relevant finding in the absence of a prospective trial as chemotherapy after radiation has been shown to increase the risk of CNS-radionecrosis by approximately fivefold [28] . Although feasibility has been established [29] [30] [31] and stereotactic radiotherapy is readily available in Switzerland, none of the patients in our series was treated with radiosurgery.
Various chemotherapeutics were used for salvage treatment including anti-VEGF treatment with bevacizumab. Still, efficacy of salvage chemotherapy was low with a median PFS of 2.6 months (range 1-50 months) and a PFS after 6 months of 18 %. LG-BSG, blue line) and high-grade brainstem gliomas (HG-BSG, green line) (n = 19). Pilocytic astrocytomas (n = 2) were excluded from outcome analysis Our study has several limitations due to its retrospective design and the small cohort size. Treatment recommendations for HG-and LG-BSG cannot be deduced. In the absence of standardization, the definition of clinical and radiological progression relied on the discretion of the physician. Furthermore, genetically data were scarce and do not provide any new clues for the molecular characterization of adult BSGs. However, it is the largest study reported so far distinctively investigating outcome of histologically verified adult BSG.
In conclusion, histologically verification of BSGs is feasible, has an impact on the therapeutic strategy and avoids false diagnoses which require different treatment approaches. The benefit of a correct diagnosis has to be weight against the risk of brainstem surgery on an individual decision basis. Given the relatively good prognosis in LG-BSG achieved with no postoperative treatment or radiotherapy alone potential harmful therapies can be avoided by histologically verified tumor grading. In contrast, given the worse prognosis of HG-BSGs combined radiochemotherapy with temozolomide should be an option due to low additional toxicity albeit the lacking evidence of efficacy. Future approaches in HG-BSGs may investigate benefits from adding bevacizumab to radiochemotherapy as it may contribute to anti-tumor effects and prevent side effects from radiotherapy in higher doses in this eloquent brain region.
